StockData
Shoulder Innovations, Inc. logo

Shoulder Innovations, Inc. (SI) company profile

SINYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3051% above fair value
$20.56+0.11 (+0.54%)

Close on Nov 17, 2026Market cap $428.04MP/E –Yield –

About Shoulder Innovations

Surgical & Medical Instruments & Apparatus, SIC 3841

The company develops and commercializes medical technology solutions focused on shoulder surgical care. Its offerings center on advanced implant systems for anatomic and reverse total shoulder arthroplasty, featuring proprietary glenoid and humeral stem technologies designed to improve stability and joint biomechanics. Complementing its implants, the company provides AI- and machine-learning-driven preoperative planning software that converts medical scans into 3D patient models, alongside a streamlined two-tray surgical instrumentation system. It serves orthopedic surgeons, hospitals, and outpatient surgery centers, supported by specialized clinical personnel and independent distributors.

The business operates commercially within the United States, targeting high-volume orthopedic surgeons across inpatient facilities and ambulatory surgery centers. Its implant portfolio has been utilized in more than 17,500 surgical procedures. Commercial and clinical operations are supported by a field team of 45 shoulder specialists collaborating with a third-party distributor network. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Shoulder Innovations's latest annual report, written by StockData.

Company profile

Company

Legal name
Shoulder Innovations, Inc.
Headquarters
Grand Rapids, MI
Address
1535 Steele Avenue Sw, Suite B 49507
Phone
(616) 294-1026
Employees
75, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Grand Rapids, Michigan

Stock & identifiers

Ticker
SI
Exchange
NYSE
IPO date
Aug 1, 2025
Shares outstanding
21M, Jul 30, 2026
Filer category
<br>Emerging growth company
SEC CIK
1699350
CUSIP
82537J108
ISIN
US82537J1088
FIGI
BBG00FM5V7M6
Share class FIGI
BBG00FM5V7N5
LEI
529900LTH37ALD2K7437
EIN
27-0538764

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Robert Joseph BallCEO & Executive Chairman, Director417,942
Matthew Fraser AhearnChief Operating Officer, Director245,776
Jonathan E. OsborneChief Commercial Officer60,355
Jeffrey S. PointsChief Financial Officer68,835
David Lawrence BlueSee Remarks139,372
Kevin K. SidowDirector25,948
Casey M. TanseyDirector2,746,564
Paul BuckmanDirector65,025
Andrew HykesDirector7,438
Richard BuchholzDirector18,712
Michael A. CarusiDirector1,626,136
Geoffrey B. PardoDirector2,288,148

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
Robert Ball
Chief Executive Officer
$467.94K–$494.13K$224.61K$15.80K$1.20M+91%
Jeffrey Points
Chief Financial Officer
$378.14K$50.00K$98.83K$181.51K$11.34K$719.82K+42%
David L. Blue
Chief Customer Experience Officer
$364.46K–$148.24K$247.10K$18.98K$778.77K+57%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 1, 2025
Offer price
$15.00
Securities offered
5,000,000
Gross proceeds
$75.00M
Exchange
NYSE
Lock-up ends (est.)
Jan 28, 2026

“Per Share Total Initial public offering price $15.00 $75,000,000 Underwriting discounts and commissions (1) $1.05 $5,250,000 Proceeds, before expenses, to us $13.95 $69,750,000 __________________ (1) See the section titled “ Underwriting ” for additional disclosure regarding the estimated underwriting discounts and”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?